3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Urinary Bladder Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma in Situ
1
Interventions
Bevacizumab
39
Paclitaxel
35
pembrolizumab
27
Carboplatin
27
Specimen Handling
21
olaparib
19
Magnetic Resonance Spectroscopy
19
Gemcitabine
19
liposomal doxorubicin
17
Cyclophosphamide
16
niraparib
13
fludarabine
12
Topotecan
12
Cisplatin
12
Biopsy
12
Taxes
9
Nivolumab
8
Immunoglobulin G
8
Fulvestrant
8
Doxorubicin
8
Disulfides
8
Surveys and Questionnaires
7
palbociclib
6
aldesleukin
6
Oxaliplatin
6
Letrozole
5
Fluorouracil
5
trastuzumab deruxtecan
4
oregovomab
4
mirvetuximab soravtansine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Histamine Antagonists
×
90 days
×
Clear all
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled